Aprocitentan
- Generic Name
- Aprocitentan
- Brand Names
- Jeraygo
- Drug Type
- Small Molecule
- Chemical Formula
- C16H14Br2N6O4S
- CAS Number
- 1103522-45-7
- Unique Ingredient Identifier
- MZI81HV01P
- Background
Aprocitentan is under investigation in clinical trial NCT03541174 (A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety).
A Drug-drug Interaction Trial in Healthy Female Participants to Investigate the Effect of Aprocitentan on Combined Hormonal Contraceptives
- Conditions
- Drug Drug Interaction
- Interventions
- Drug: Ethinyl Estradiol / Levonorgestrel Oral Tablet
- First Posted Date
- 2025-01-29
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 19
- Registration Number
- NCT06799884
- Locations
- 🇨🇿
CEPHA s.r.o., Pilsen, Czechia
Bioequivalence Study of Different Aprocitentan Tablet Formulations
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT05196399
- Locations
- 🇨🇿
CEPHA s.r.o., Pilsen, Czechia
To Study the Effect of Aprocitentan on the Electrical Activity of the Heart in Healthy Men and Women
- Conditions
- Healthy Subjects
- Interventions
- Drug: Matching placeboOther: Moxifloxacin control to establish assay sensitivity
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT04281342
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Baden-Württemberg, Germany
The Effect of Hepatic Impairment on Aprocitentan Pharmacokinetics
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 17
- Registration Number
- NCT04252495
- Locations
- 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
🇵🇱Biokinetica S.A., Jozefow, Poland
A Research Study to Show Aprocitentan is Efficacious and Safe to Treat Patients With Uncontrolled Blood Pressure and Chronic Kidney Disease.
- Conditions
- HypertensionRenal Insufficiency, Chronic
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-11-14
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Registration Number
- NCT04162366
A Study to Evaluate How Aprocitentan is Safe and How it is Absorbed and Broken Down in the Body of Japanese and Caucasian Subjects
- First Posted Date
- 2018-07-13
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT03586570
- Locations
- 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety
- Conditions
- Resistant Hypertension
- Interventions
- First Posted Date
- 2018-05-30
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 730
- Registration Number
- NCT03541174
- Locations
- 🇺🇸
TLM Medical Services LLC, Columbia, South Carolina, United States
🇺🇸Academic Medical Research Institute Inc, Los Angeles, California, United States
🇺🇸California Kidney Specialists, San Dimas, California, United States
A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-132577 Can Affect Rosuvastatin's Fate in the Body (Amount and Time of Presence in the Blood)
- First Posted Date
- 2017-08-10
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT03245229
- Locations
- 🇨🇿
Cepha s.r.o, Plzen, Czechia
A Study to Evaluate ACT-132577 in Healthy Subjects and in People With Severe Kidney Disease
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT03165071
- Locations
- 🇨🇿
CEPHA, Plzen, Czechia
A Study to Evaluate ACT-132577 in Healthy Male Subjects
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT03100591
- Locations
- 🇳🇱
PRA Health Sciences, Groningen, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.